From April 2021, the Dermapharm subsidiary Allergopharm also produced the Corona vaccine Comirnaty from Biontech.
(Photo: imago images/photothek)
Dusseldorf The Bavarian drug manufacturer Dermapharm wants to take over the French competitor Arkopharma. “The planned acquisition will strengthen our international presence in Western Europe and give us access to the French market for the first time,” said Dermapharm CEO Hans-Georg Feldmeier.
The company from Grünwald near Munich, which is listed in the SDax, offers the financial investor Montagu Private Equity around 450 million euros for Arkopharma. The French group was founded in 1980 and manufactures over-the-counter herbal medicines and dietary supplements at its headquarters in Carros near Nice. According to Dermapharm, Arkopharma is the French market leader for natural medicines.
In the current year, Arkopharma wants to achieve sales of around 200 million euros. According to media reports, the operating profit (Ebitda) was around 45 million euros.
At the end of last year, Dermapharm took over the C³ Group from the Canadian cannabis group Canopy Growth for around 80 million euros. The company is active in the medical cannabis business.
Top jobs of the day
Find the best jobs now and
be notified by email.
Last year, Dermapharm achieved sales of 943 million euros and an operating result (Ebitda) of a good 354 million euros. The company is worth around three billion euros on the stock exchange and will gain around a fifth of its sales as a result of the takeover, and around an eighth of its operating profit. Arkopharma’s Ebitda margin is around 24 percent.
Dermapharm did not comment on the financing of the acquisition. Dermapharm also expects new access to the Belgian, Portuguese and Dutch markets from the acquisition. In addition, the company wants to expand its own presence in Italy and Spain with the Arkopharma offer.
The employee representatives of the Arkopharma Group still have to approve the takeover, Dermapharm expects the acquisition to be completed at the beginning of January 2023.
More: Billions in business with corona drugs: Pfizer increases profit forecast